» Articles » PMID: 37373181

High Plasma Angiopoietin-2 Levels Predict the Need to Initiate Dialysis Within Two Years in Patients with Chronic Kidney Disease

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2023 Jun 28
PMID 37373181
Authors
Affiliations
Soon will be listed here.
Abstract

Volume status, congestion, endothelial activation, and injury all play roles in glomerular filtration rate (GFR) decline. In this study, we aimed to determine whether the plasma endothelial and overhydration markers could serve as independent predictors for dialysis initiation in patients with chronic kidney disease (CKD) 3b-5 (GFR < 45 mL/min/1.72 m) and preserved ejection fraction. A prospective, observational study in a single academic center was conducted from March 2019 to March 2022. Plasma levels of angiopoietin (Ang)-2, Vascular Endothelial Growth Factor-C (VEGF-C), Vascular Cell Adhesion Molecule-1 (VCAM-1), Copeptin (CPP), beta-trace protein (BTP), brain natriuretic peptide (BNP), and cardiac troponin I (cTnI) were all measured. Lung ultrasound (US) B-lines, bioimpedance, and echocardiography with global longitudinal strain (GLS) were recorded. The study outcome was the initiation of chronic dialysis (renal replacement therapy) during 24 months of follow-up. A total of 105 consecutive patients with a mean eGFR of 21.3 mL/min/1.73 m were recruited and finally analyzed. A positive correlation between Ang-2 and VCAM-1 and BTP was observed. Ang-2 correlated positively with BNP, cTnI, sCr, E/e', and the extracellular water (ECW)/intracellular water (ICW) ratio (ECW/ICW). After 24 months, a deterioration in renal function was observed in 47 patients (58%). In multivariate regression analysis, both VCAM-1 and Ang-2 showed independent influences on risk of renal replacement therapy initiation. In a Kaplan-Meier analysis, 72% of patients with Ang-2 concentrations below the median (3.15 ng/mL) survived without dialysis for two years. Such an impact was not observed for GFR, VCAM, CCP, VEGF-C, or BTP. Endothelial activation, quantified by plasma levels of Ang-2, may play a key role in GFR decline and the need for dialysis initiation in patients with CKD 3b, 4, and 5.

Citing Articles

Exploring Angiopoietin-2: Clinical Insights and Experimental Perspectives in Kidney Diseases.

Luo A, Chang F, Lin S Kidney Int Rep. 2024; 9(12):3375-3385.

PMID: 39698365 PMC: 11652073. DOI: 10.1016/j.ekir.2024.09.001.


New Diagnostic and Therapeutic Approaches in Diabetic Microvascular Complications.

Serban D, Dascalu A Biomedicines. 2024; 12(8).

PMID: 39200322 PMC: 11351895. DOI: 10.3390/biomedicines12081858.

References
1.
Lobov I, Brooks P, Lang R . Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo. Proc Natl Acad Sci U S A. 2002; 99(17):11205-10. PMC: 123234. DOI: 10.1073/pnas.172161899. View

2.
Mansour S, Bhatraju P, Coca S, Obeid W, Wilson F, Stanaway I . Angiopoietins as Prognostic Markers for Future Kidney Disease and Heart Failure Events after Acute Kidney Injury. J Am Soc Nephrol. 2022; 33(3):613-627. PMC: 8975075. DOI: 10.1681/ASN.2021060757. View

3.
Mallamaci F, Benedetto F, Tripepi R, Rastelli S, Castellino P, Tripepi G . Detection of pulmonary congestion by chest ultrasound in dialysis patients. JACC Cardiovasc Imaging. 2010; 3(6):586-94. DOI: 10.1016/j.jcmg.2010.02.005. View

4.
Bontekoe J, Lee J, Bansal V, Syed M, Hoppensteadt D, Maia P . Biomarker Profiling in Stage 5 Chronic Kidney Disease Identifies the Relationship between Angiopoietin-2 and Atrial Fibrillation. Clin Appl Thromb Hemost. 2018; 24(9_suppl):269S-276S. PMC: 6707900. DOI: 10.1177/1076029618808909. View

5.
Lv J, Zhang L . Prevalence and Disease Burden of Chronic Kidney Disease. Adv Exp Med Biol. 2019; 1165:3-15. DOI: 10.1007/978-981-13-8871-2_1. View